ERBB2 and breast cancer: The phase 2 NCT05007444 study with P2Et (a standardized extract of tara (Caesalpinia spinosa (Molina) Kuntze, Fabaceae) in addition to standard neoadjuvant therapy is being performed on BC patients (not eligible for anti-HER-2 treatment) in order to assess optimal biological dose of P2Et based on its toxicological profile and other parameters as secondary endpoints.